Aerosolized antifungal prophylaxis: The winds of change?

Clinical Infectious Diseases

Volumn 46, Issue 9, 2008, Pages 1409-1411

  Perfect, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; PLACEBO;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CLINICAL TRIAL; COUGHING; DRUG COST; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG LAVAGE; MEDICAL RESEARCH; NOTE; PRIORITY JOURNAL; PROPHYLAXIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; HUMANS; LUNG DISEASES, FUNGAL; NEUTROPENIA;

EID: 42549119120     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/586740     Document Type: Note

References (10)

1. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: randomized, placebo-controlled trial. Clin Infect Dis 2008; 46:1401-8 (in this issue).
2. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
3. Ullmann A J, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-47.
4. Schwartz S, Behre G, Heinemann V. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia. Blood 1999; 93:3654-61.
5. Perfect JR. Antifungal prophylaxis: to prevent or not. Am J Med 1993; 94:233-4.
6. Palmer SM, Whitehouse JD, Drew RD, et al. Aerosolized amphotericin B lipid complex: a novel approach to the prophylaxis of fungal infections after lung transplantation. Transplantation 2001; 72:545-8.
7. Drew RH, Dodds AE, Benjamin DK Jr, Duane DR, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77:232-7.
8. Menzin J, Jackel J, Friedman M, Perfect JR, Langston A, Papadopoulous G. Clinical and economic burden of invasive fungal infections among hospitalized patients: findings from a national database [abstract 0-1869]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). 2007.
9. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case - fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358-66.
10. Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008; 46:120-8.